Search results
Showing 8041 to 8055 of 9024 results
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]
Discontinued Reference number: GID-TA11421
Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]
Discontinued Reference number: GID-TA10958
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]
Discontinued Reference number: GID-TA11020
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]
Discontinued Reference number: GID-TA11108
In development Reference number: GID-TA11014 Expected publication date: TBC
Dexmedetomidine for treating agitation associated with schizophrenia [TSID10726]
In development Reference number: GID-TA11015 Expected publication date: TBC
In development Reference number: GID-TA11646 Expected publication date: TBC
In development Reference number: GID-TA11327 Expected publication date: TBC
Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]
Discontinued Reference number: GID-TA11240
In development Reference number: GID-TA11909 Expected publication date: TBC
Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]
Discontinued Reference number: GID-TA11178
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]
Discontinued Reference number: GID-TA11128
This guideline has been updated and replaced by NICE guideline NG257.
Palforzia for treating peanut allergy in children and young people (TA769)
NICE has withdrawn this guidance. This is because Stallergenes Greer have discontinued the Palforzia initial dose escalation pack. No new people will start taking Palforzia in the UK. Healthcare professionals should discuss alternative treatment options. People currently having Palforzia will be able to continue until March 2027.
In development Reference number: GID-TA11771 Expected publication date: TBC